A case-control study of unilateral and bilateral breast carcinoma patients

Newman, Lisa A.; Sahin, A.; Bondy, Melissa L.; Mirza, Nadeem Q.; Vlastos, George; Whitman, Gary J.; Brown, Heather M.; Buchholz, Thomas A.; Lee, Mong‐Hong; Singletary, S. Eva

doi:10.1002/1097-0142(20010515)91:10<1845::aid-cncr1205>3.0.co;2-z

Cited by 78 publications

(76 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…International evidence of the prognostic significance of SBBC is not consistent, although most studies suggest that these cancers have either an equivalent or moderately poorer survival compared with unilateral cases (Gollamudi et al, 1997;Heron et al, 2000;Kollias et al2001;Newman et al 2001;Jobsen et al, 2003;Polednak, 2003;Tousimis, 2005;Beckmann et al, 2011). Differences in results may reflect variations in definition of synchronicity or differences in patient risk profile (Tousimis, 2005).…”

Section: Discussionmentioning

confidence: 99%

“…System features such as case load and private health insurance status were also entered but Asian Pacific Journal of Cancer Prevention, Vol 13, 2012 1415 DOI:http://dx.doi.org/10.7314/APJCP.2012.13.4.1413 they were not associated with SBBC status (p≥0.187) and were not expected to confound relationships of SBBC status with survival. Although treatment protocols may affect relative outcomes by SBBC status, they were not included in this initial study which, like most previous studies (Gollamudi et al, 1997;Heron et al, 2000;Kollias et al, 2001;Newman et al, 2001;Jobsen et al, 2003;Polednak, 2003;Tousimis, 2005;Beckmann et al, 2011), focused on pre-treatment prognostic factors.…”

Section: Methodsmentioning

confidence: 99%

“…Evidence of the prognostic significance of synchronous bilateral compared with unilateral breast cancer is available from a number of studies (Gollamudi et al, 1997;Heron et al, 2000;Kollias et al, 2001;Newman et al, 2001;Jobsen et al, 2003;Polednak, 2003;Tousimis, 2005;Beckmann et al, 2011). While results vary, most indicate that synchronous bilateral breast cancers (SBBC) have either an equivalent or moderately poorer survival compared with unilateral cases.…”

Section: Introductionmentioning

confidence: 99%

“…By comparing observed survivals with survivals predicted by these models, shortfalls can be identified for guiding quality improvement initiatives. The relevance of including SBBC in such models is uncertain from the international evidence (Gollamudi et al, 1997;Heron et al, 2000;Kollias et al, 2001;Newman et al, 2001;Jobsen et al, 2003;Polednak, 2003;Tousimis, 2005;Beckmann et al, 2011) and is investigated in this study, using the Audit database.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Survival From Synchronous Bilateral Breast Cancer: The Experience of Surgeons Participating in the Breast Audit of the Society of Breast Surgeons of Australia and New Zealand

Roder

Silva²,

Zorbas³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Previous studies generally indicate that synchronous bilateral breast cancers (SBBC) have an equivalent or moderately poorer survival compared with unilateral cases. The prognostic characteristics of SBBC would be relevant when planning adjuvant therapies and follow-up medical surveillance. The frequency of SBBC among early breast cancers in clinical settings in Australia and New Zealand was investigated, plus their prognostic significance, using the Breast Cancer Audit Database of the Society of Breast Surgeons of Australia and New Zealand, which covered an estimated 60% of early invasive lesions in those countries. Design: Rate ratios (95% confidence limits) of SBBC were investigated among 35,370 female breast cancer cases by age of woman, histology type, grade, tumour diameter, nodal status, lymphatic/vascular invasion and oestrogen receptor status. Univariate and multivariable disease-specific survival analyses were undertaken. Results: 2.3% of cases were found to be SBBC (i.e., diagnoses occurring within 3 months). The figure increased from 1.4% in women less than 40 years to 4.1% in those aged 80 years or more. Disease-specific survivals did not vary by SBBC status (p=0.206). After adjusting for age, histology type, diameter, grade, nodal status, lymphatic/vascular invasion, and oestrogen receptor status, the relative risk of breast cancer death for SBBC was 1.17 (95% CL: 0.91, 1.51). After adjusting for favourable prognostic factors more common in SBBC cases (i.e., histology type, grade, lymphatic/ vascular invasion, and oestrogen receptor status), the relative risk of breast cancer death for SBBC was 1.42 (95% CL: 1.10, 1.82). After adjusting for unfavourable prognostic factors more common in SBBC cases (i.e., older age and large tumour diameter), the relative risk of breast cancer death for SBBC was 0.98 (95% CL: 0.76, 1.26). Conclusions: Results confirm previous findings of an equivalent or moderately poorer survival for SBBC but indicate that SBBC status is likely to be an important prognostic indicator for some cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Survival From Synchronous Bilateral Breast Cancer: The Experience of Surgeons Participating in the Breast Audit of the Society of Breast Surgeons of Australia and New Zealand

Roder

Silva²,

Zorbas³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Similar results have been reported by Tulusan et al 13 In that study, the diagnosis of multifocality was based on a random biopsy of the contralateral breast. Newman et al 29 showed that SBIBC was more likely to show multicentric disease. In other studies, 39,40,43 multicentricity was a significant risk factor for the development of bilateral breast carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution

Intra

Rotmensz

Viale

et al. 2004

Cancer

View full text Add to dashboard Cite

BACKGROUNDSynchronous bilateral invasive breast carcinoma (SBIBC) ranged in incidence from 0.3% to as high as 12%.METHODSBetween April 1997 and February 2003, 143 consecutive patients with SBIBC were treated at the European Institute of Oncology (Milan, Italy). Their information was collected prospectively in a database. The bilateral tumors were divded into left and right tumors. Tumor size, histology, grade, lymph node status, estrogen (ER) and progesterone receptor (PgR) status, HER‐2 expression, peritumoral vascular invasion (PVI), Ki‐67 expression, extensive in situ component (EIC), and multifocality between the two groups were analyzed. During the same time period, 6218 patients with unilateral invasive breast carcinoma (UIBC) were analyzed in the same manner for comparison with the patients with SBIBC.RESULTSThere were no significant differences between left and right tumors, and the observed histopathologic agreement within the same patient was significantly superior than statistically expected for all characteristics except size, lymph node status, and multifocality. When compared with patients with UIBC, patients with SBIBC were more likely to present with smaller tumors and showed a higher frequency of invasive lobular carcinoma, lower histologic grade, higher rate of ER and PgR positivity, and lower PVI and Ki‐67 expression.CONCLUSIONSThe high concordance of histopathologic characteristics between SBIBC within the same patient could reflect a particular hormonal environment that influenced either the initiation and development of these lesions simultaneously and independently from the single or multi‐clonal origin, either a less aggressive biological behavior compared with UIBC. In particular, the strong agreement of the observed EIC in SBIBC within the same patient seemed to definitively exclude the metastatic origin of these tumors. Cancer 2004. © 2004 American Cancer Society.

show abstract

Contralateral Prophylactic Mastectomy

Newman

2014

JAMA

View full text Add to dashboard Cite

A case-control study of unilateral and bilateral breast carcinoma patients

Cited by 78 publications

References 38 publications

Survival From Synchronous Bilateral Breast Cancer: The Experience of Surgeons Participating in the Breast Audit of the Society of Breast Surgeons of Australia and New Zealand

Survival From Synchronous Bilateral Breast Cancer: The Experience of Surgeons Participating in the Breast Audit of the Society of Breast Surgeons of Australia and New Zealand

Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution

Contralateral Prophylactic Mastectomy

Contact Info

Product

Resources

About